Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Macular Degeneration Research
Current Award

Dr. Jing Chen

Jing Chen, Ph.D.

Boston Children's Hospital
Boston, MA

Title: Control of Neovascular AMD by Nuclear Receptor RORalpha
Non-Technical Title: A New Mechanism Linking Lipid and Altered Inflammation in Neovascular AMD

Duration: July 1, 2013 - June 30, 2015
Award Type: Standard
Award Amount: $120,000

Summary:

A major cause of blindness in AMD is abnormal blood vessel growth in the back of the eye (choroidal neovascularization), the “wet” form of AMD. The proposed work will help define a novel pathway linking dysregulation of lipid homeostasis (fat levels) with altered inflammatory responses in AMD. Both processes are fundamentally important to the development and progression of wet AMD. Dr. Chen’s discoveries may help to develop a new way to treat AMD by specifically changing the levels of a lipid sensing nuclear receptor protein that modifies inflammation.

Details:

In preliminary studies, Dr. Chen and her collaborators linked the presence of significant genetic changes to the nuclear receptor, RORalpha (retinoic-acid-receptor-related orphan receptor alpha), with the risk of developing wet AMD. However, it is not known if RORalpha contributes to the progression of wet AMD. In this project, Dr. Chen’s team will determine whether RORalpha, as a sensor of lipid homeostasis, influences the development of wet AMD by causing changes in tissue inflammation. The analysis will be done with both genetic (DNA) and pharmacologic (small molecule drug) approaches to modulate RORalpha activity in animal models of AMD.

AMD is a complex disease linked to problems with lipid metabolism, and inflammation/immune functions. A more integrated treatment approach that corrects more than one of the mechanisms that can lead to AMD, such as problems with inflammation and lipid metabolism, would be of great benefit. When this study is complete, it will identify a novel control mechanism in wet AMD that links two major pathways contributing to AMD, and provide clues to a new therapeutic approach to treat this blinding eye disease.

Investigator Biography:

Dr. Chen is an Assistant Professor of Ophthalmology at Boston Children’s Hospital. She received her Ph.D. degree from Boston University and completed her postdoctoral training at Boston Children’s Hospital. Dr. Chen’s work focuses on understanding the causes and identifying potential therapies to treat pathologic blood vessel growth in vascular eye diseases, including the wet form of age-related macular degeneration.

::

]]